These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 20703486

  • 1. Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex.
    Yalon M, Ben-Sira L, Constantini S, Toren A.
    Childs Nerv Syst; 2011 Jan; 27(1):179-81. PubMed ID: 20703486
    [Abstract] [Full Text] [Related]

  • 2. Everolimus tablets for patients with subependymal giant cell astrocytoma.
    Turner SG, Peters KB, Vredenburgh JJ, Desjardins A, Friedman HS, Reardon DA.
    Expert Opin Pharmacother; 2011 Oct; 12(14):2265-9. PubMed ID: 21806479
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA).
    Ebrahimi-Fakhari D, Franz DN.
    Expert Opin Pharmacother; 2020 Aug; 21(11):1329-1336. PubMed ID: 32338549
    [Abstract] [Full Text] [Related]

  • 4. Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Józwiak S, Stein K, Kotulska K.
    Future Oncol; 2012 Dec; 8(12):1515-23. PubMed ID: 23231513
    [Abstract] [Full Text] [Related]

  • 5. Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Major P.
    Aging (Albany NY); 2011 Mar; 3(3):189-91. PubMed ID: 21415462
    [Abstract] [Full Text] [Related]

  • 6. Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex.
    Cappellano AM, Senerchia AA, Adolfo F, Paiva PM, Pinho R, Covic A, Cavalheiro S, Saba N.
    Childs Nerv Syst; 2013 Dec; 29(12):2301-5. PubMed ID: 23743818
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
    Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S.
    Lancet; 2013 Jan 12; 381(9861):125-32. PubMed ID: 23158522
    [Abstract] [Full Text] [Related]

  • 8. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Kotulska K, Chmielewski D, Borkowska J, Jurkiewicz E, Kuczyński D, Kmieć T, Łojszczyk B, Dunin-Wąsowicz D, Jóźwiak S.
    Eur J Paediatr Neurol; 2013 Sep 12; 17(5):479-85. PubMed ID: 23567018
    [Abstract] [Full Text] [Related]

  • 9. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Cardamone M, Flanagan D, Mowat D, Kennedy SE, Chopra M, Lawson JA.
    J Pediatr; 2014 May 12; 164(5):1195-200. PubMed ID: 24518170
    [Abstract] [Full Text] [Related]

  • 10. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex.
    Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR.
    Ann Neurol; 2006 Mar 12; 59(3):490-8. PubMed ID: 16453317
    [Abstract] [Full Text] [Related]

  • 11. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.
    Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN.
    N Engl J Med; 2010 Nov 04; 363(19):1801-11. PubMed ID: 21047224
    [Abstract] [Full Text] [Related]

  • 12. Response of subependymal giant cell astrocytoma with spinal cord metastasis to everolimus.
    Aguilera D, Flamini R, Mazewski C, Schniederjan M, Hayes L, Boydston W, Castellino RC, MacDonald TJ.
    J Pediatr Hematol Oncol; 2014 Oct 04; 36(7):e448-51. PubMed ID: 24276039
    [Abstract] [Full Text] [Related]

  • 13. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
    Franz DN.
    Expert Rev Anticancer Ther; 2011 Aug 04; 11(8):1181-92. PubMed ID: 21916571
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP, Krueger DA.
    Neuro Oncol; 2015 Dec 04; 17(12):1550-9. PubMed ID: 26289591
    [Abstract] [Full Text] [Related]

  • 16. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.
    Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Berkowitz N, Anak O, Niolat J, Jozwiak S.
    Lancet Oncol; 2014 Dec 04; 15(13):1513-1520. PubMed ID: 25456370
    [Abstract] [Full Text] [Related]

  • 17. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
    Weidman DR, Pole JD, Bouffet E, Taylor MD, Bartels U.
    Pediatr Blood Cancer; 2015 Oct 04; 62(10):1754-60. PubMed ID: 25929843
    [Abstract] [Full Text] [Related]

  • 18. Is mTOR inhibition a systemic treatment for tuberous sclerosis?
    Moavero R, Coniglio A, Garaci F, Curatolo P.
    Ital J Pediatr; 2013 Sep 17; 39():57. PubMed ID: 24044547
    [Abstract] [Full Text] [Related]

  • 19. [Response to everolimus in patients with giant cell astrocytoma associated to tuberous sclerosis complex].
    Mateos-González ME, López-Laso E, Vicente-Rueda J, Camino-León R, Fernández-Ramos JA, Baena-Gómez MA, Peña-Rosa MJ.
    Rev Neurol; 2014 Dec 01; 59(11):497-502. PubMed ID: 25418144
    [Abstract] [Full Text] [Related]

  • 20. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.
    Kingswood JC, Jozwiak S, Belousova ED, Frost MD, Kuperman RA, Bebin EM, Korf BR, Flamini JR, Kohrman MH, Sparagana SP, Wu JY, Brechenmacher T, Stein K, Berkowitz N, Bissler JJ, Franz DN.
    Nephrol Dial Transplant; 2014 Jun 01; 29(6):1203-10. PubMed ID: 24729041
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.